ICON Public (NASDAQ:ICLR) Price Target Increased to $363.00 by Analysts at Robert W. Baird

ICON Public (NASDAQ:ICLR) had its target price raised by Robert W. Baird from $362.00 to $363.00 in a research report released on Friday, Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

Several other research firms have also weighed in on ICLR. Evercore ISI upped their target price on ICON Public from $325.00 to $350.00 and gave the company an outperform rating in a report on Friday, February 23rd. Barclays upped their target price on ICON Public from $325.00 to $355.00 and gave the company an overweight rating in a report on Friday, February 23rd. Mizuho restated a buy rating and issued a $346.00 price objective on shares of ICON Public in a research report on Thursday, April 4th. Finally, Truist Financial upped their price objective on ICON Public from $357.00 to $367.00 and gave the company a buy rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, ICON Public has an average rating of Moderate Buy and an average target price of $321.64.

ICON Public Trading Up 2.7 %

Shares of ICLR stock opened at $308.31 on Friday. The business’s fifty day moving average price is $318.89 and its 200 day moving average price is $282.81. ICON Public has a 1-year low of $181.92 and a 1-year high of $344.77. The firm has a market capitalization of $25.44 billion, a PE ratio of 37.51, a P/E/G ratio of 1.42 and a beta of 1.15. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.21 and a quick ratio of 1.21.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.13. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.08 billion. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. As a group, sell-side analysts forecast that ICON Public will post 14.4 EPS for the current fiscal year.

Hedge Funds Weigh In On ICON Public

Large investors have recently added to or reduced their stakes in the business. Liontrust Investment Partners LLP lifted its position in ICON Public by 108.4% during the third quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock worth $22,129,000 after buying an additional 46,739 shares during the period. Chartwell Investment Partners LLC raised its holdings in shares of ICON Public by 16.1% in the 3rd quarter. Chartwell Investment Partners LLC now owns 6,953 shares of the medical research company’s stock worth $1,712,000 after purchasing an additional 963 shares during the period. Whittier Trust Co. raised its holdings in shares of ICON Public by 6.2% in the 4th quarter. Whittier Trust Co. now owns 2,702 shares of the medical research company’s stock worth $765,000 after purchasing an additional 158 shares during the period. Cullen Investment Group LTD. purchased a new position in shares of ICON Public in the 4th quarter worth about $1,620,000. Finally, Prime Capital Investment Advisors LLC purchased a new position in shares of ICON Public in the 4th quarter worth about $416,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.